Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
-
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
-
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
-
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
-
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
-
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
-
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
-
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
-
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
-
Aclarion Appoints Greg Gould as Chief Financial Officer